Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01390584 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
A Phase 2 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01390584 is a Phase 2 study that was terminated before completion, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 6 participants.
The verdict
NCT01390584, a Phase 2 study, was terminated before completion, sponsored by ECOG-ACRIN Cancer Research Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine, dacarbazine, cyclophosphamide, etoposide, procarbazine hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. Comparing results of imaging procedures, such as PET scans and CT scans, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II clinical trial studies how well chemotherapy based on PET/CT scan works in treating patients with stage I or stage II Hodgkin lymphoma.
Interventions
- DRUG Doxorubicin
- DRUG Vinblastine
- RADIATION INRT
- DRUG Bleomycin
- DIAGNOSTIC_TEST PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-05-24 |
| Est. Completion | 2018-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01390584
The ClinicalTrials.gov registry entry for NCT01390584 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT01390584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01390584 about?
NCT01390584 is a clinical study titled "Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma". RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine, dacarbazine, cyclophosphamide, etoposide, procarbazine hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells ...
What is the current status of trial NCT01390584?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2013-05-24. Estimated completion is 2018-05-18.
What interventions are being tested in trial NCT01390584?
The interventions under investigation include: Doxorubicin (DRUG), Vinblastine (DRUG), INRT (RADIATION), Bleomycin (DRUG), PET (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01390584?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.